Literature DB >> 3698020

Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.

G J Goldenberg, H Wang, G W Blair.   

Abstract

Cloned lines of Adriamycin (ADR)-sensitive and -resistant P388 leukemia have been established from single cell cultures. A marker chromosome M1 was found in all cells in the heterogeneous resistant P388/ADR parental line as well as in the cloned resistant lines P388/ADR/3 and P388/ADR/7; a different marker chromosome M2 was present in the heterogeneous sensitive P388 parental line as well as the cloned sensitive line P388/4. Dose-survival studies showed that D0, the dose of Adriamycin reducing survival to 1/e (i.e., 37% of the initial population), was 33 +/- 5 (SE) nM for sensitive P388/4 cells, 169 +/- 17 nM for resistant P388/ADR/3 cells, and 336 +/- 28 nM for the more resistant P388/ADR/7 cells. Drug uptake in sensitive P388/4 cells was 1.6-fold greater than in resistant P388/ADR/3 cells and 2.1-fold greater than in resistant P388/ADR/7 cells. The number of DNA single-strand breaks produced per microM Adriamycin was 131 +/- 9 rad equivalents in sensitive clone 4 cells, 41 +/- 8 rad equivalents in resistant clone 3 cells, and 33 +/- 11 rad equivalents in resistant clone 7 cells. The number of DNA double-strand breaks per microM Adriamycin was 1721 +/- 126 rad equivalents in sensitive cells, 117 +/- 36 rad equivalents in resistant P388/ADR/3 cells, and 194 +/- 16 rad equivalents in resistant P388/ADR/7 cells. Differences in drug uptake were insufficient to explain the higher incidence of DNA single- and double-strand breaks in sensitive cells. These findings strongly support the concept that resistance to Adriamycin in P388 leukemia cells is multifactorial; however, this study did not resolve whether these changes arise from a single pleiotropic mutation or from multiple mutations. In sensitive P388/4 cells the number of DNA single-strand breaks formed could all be attributed to double-strand breaks. However, in both resistant cell lines the level of induction of single-strand breaks was in excess of that due to double-strand breaks, and this excess of single-strand breaks appeared to vary directly with the degree of resistance, being greater in the more resistant clone 7 cells than in the less resistant clone 3 cells. In both sensitive and resistant cell lines the ratio of true single- to double-strand breaks varied inversely with the concentration of Adriamycin. Finally, the cytotoxic activity of Adriamycin appeared to correlate more closely with formation of DNA double-strand breaks than with single-strand lesions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698020

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.

Authors:  Olga V Leontieva; Maria N Preobrazhenskaya; Ralph J Bernacki
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

2.  Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.

Authors:  Ping Ma; Russell J Mumper
Journal:  Nano Today       Date:  2013-06-01       Impact factor: 20.722

3.  Glutathione S-transferase activity of leukemic cells as a prognostic factor for response to chemotherapy in acute leukemias.

Authors:  J Koberda; A Hellmann
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

4.  Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors.

Authors:  M Koutsilieris; C Reyes-Moreno; I Choki; A Sourla; C Doillon; N Pavlidis
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

5.  Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line.

Authors:  Peter Bober; Michal Alexovic; Ivan Talian; Zuzana Tomkova; Zuzana Viscorova; Maria Benckova; Igor Andrasina; Rachele Ciccocioppo; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak; Jan Sabo
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

6.  Collateral sensitivity to radiation and cis-platinum in a multidrug-resistant human leukemia cell line.

Authors:  J Cho; Y Lee; J Lutzky; L Redpath; L Slater
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines.

Authors:  G Toffoli; A Viel; L Tumiotto; G Biscontin; C Rossi; M Boiocchi
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

8.  Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.

Authors:  Matthew Trendowski; Joan M Mitchell; Christine M Corsette; Christopher Acquafondata; Thomas P Fondy
Journal:  Invest New Drugs       Date:  2015-01-07       Impact factor: 3.850

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.